Clinical and Experimental Nephrology

, Volume 14, Issue 3, pp 239–243

The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients

  • So-Youn Park
  • Kyung-Hwan Jeong
  • Ju-Young Moon
  • Sang-Ho Lee
  • Chun-Gyoo Ihm
  • Sang Youl Rhee
  • Jeong-Taek Woo
  • In-Hwan Oh
  • Tae-Won Lee
Original Article

DOI: 10.1007/s10157-010-0272-5

Cite this article as:
Park, SY., Jeong, KH., Moon, JY. et al. Clin Exp Nephrol (2010) 14: 239. doi:10.1007/s10157-010-0272-5

Abstract

Background

Fibroblast growth factor 23 (FGF-23) is a circulating factor that acts as a phosphaturic factor in the kidneys. It is also involved in several disorders of phosphate regulation and bone metabolism. We hypothesized that increased FGF-23 levels in patients with endstage renal disease (ESRD) on maintenance hemodialysis would be associated with increased bone demineralization, and we analyzed the relationship between FGF-23 levels and bone mineral density (BMD).

Methods

The serum level of FGF-23 was measured in this cross-sectional study, whose subjects consisted of 54 patients with ESRD on maintenance hemodialysis. Clinical parameters associated with hemodialysis and bone metabolism were measured. The relationship between serum FGF-23 and BMD and the factors affecting the serum level of FGF-23 were analyzed.

Results

Serum FGF-23 levels were significantly higher in ESRD patients on maintenance hemodialysis than in normal persons (2961.4 vs. 30 pg/ml). Multiple regression analysis showed that increasing FGF-23 levels were associated with serum phosphate (r = 0.684, P < 0.001), but not with BMD or other bone metabolism factors. Factors affecting log10FGF-23 included the serum calcium phosphate product (β = 0.603) and Kt/V (integrated fractional clearance expressed per dialysis, β = −0.244). These results were also seen in an analysis of the correlations based on T score or gender.

Conclusions

FGF-23 levels were positively associated with serum phosphate levels but were not correlated with BMD. The only factors affecting log10FGF-23 were the serum calcium phosphate product and Kt/V. These findings suggest that FGF-23 may have no direct effect on bone mineralization, and further studies are warranted to examine the effects of FGF-23 on vitamin D metabolism.

Keywords

Fibroblast growth factor 23 Renal dialysis Bone density Bone demineralization, pathologic 

Copyright information

© Japanese Society of Nephrology 2010

Authors and Affiliations

  • So-Youn Park
    • 1
  • Kyung-Hwan Jeong
    • 1
  • Ju-Young Moon
    • 1
  • Sang-Ho Lee
    • 1
  • Chun-Gyoo Ihm
    • 1
  • Sang Youl Rhee
    • 2
  • Jeong-Taek Woo
    • 2
  • In-Hwan Oh
    • 3
  • Tae-Won Lee
    • 1
  1. 1.Department of NephrologyKyung Hee University School of MedicineSeoulKorea
  2. 2.Department of Endocrinology and MetabolismKyung Hee University School of MedicineSeoulKorea
  3. 3.Department of Preventive MedicineKyung Hee University School of MedicineSeoulKorea

Personalised recommendations